Amplify the possible in advanced therapy preclinical studies
AmplifyBio is a leading preclinical CRO focused on toxicology, safety, and pharmacology testing of advanced therapeutics for the betterment of human health. Spun out of Battelle in May of 2021, AmplifyBio continues to provide exceptional CRO study services, but in an agile environment better suited to commercial goals and with expanded analytic capabilities to serve the dynamic needs of advanced therapeutic development. The result for our customers is the peace of mind that comes from direct access to highly experienced study directors, scientists, and program managers with decades of experience in GLP and non-GLP study design and execution, with the benefit of rapid investment in technology and infrastructure that ensure a strong partnership. Some of those investments include a state-of-the-art dPCR lab for molecular applications, spectral flow cytometry, expansion of bead arrays and ELISA/Fluorospot for immunological and cytokine assessments, and in-vivo imaging. Additionally there has been method expansions in pathology, in-house surgical, dose routes, bone marrow collection inhalation studies, and more.